Source comparison
BPC-157 for ACL Injury Recovery: Research vs. Supplement Comparison
BPC-157 peptide Upregulates VEGF, increases fibroblast migration, stabilizes NO synthase Preclinical (animal models). No FDA-approved human trials 40-60% faster healing in rat ligament studies; improved tensile strength Most mechanistically plausible peptide f
This comparison does not assign a generated winner or score.
- BPC-157 peptide
- Upregulates VEGF, increases fibroblast migration, stabilizes NO synthase
- Preclinical (animal models). No FDA-approved human trials
- 40-60% faster healing in rat ligament studies; improved tensile strength
- Most mechanistically plausible peptide for ligament repair. Limited human data but strong biological rationale
- Collagen supplementation (Type I/III)
- Provides amino acid building blocks for endogenous collagen synthesis
- Mixed. Some human trials show tendon benefits
- Modest improvement in tendon stiffness (5-10%) in older adults
- Supportive but not mechanism-driven. Doesn't activate repair pathways, just provides substrate
- Vitamin C (ascorbic acid)
- Cofactor for prolyl hydroxylase (collagen cross-linking enzyme)
- Well-established
- Prevents scurvy-related collagen defects; no evidence it accelerates normal healing
- Essential but not rate-limiting in healthy individuals with adequate dietary intake
- PRP (Platelet-Rich Plasma)
- Delivers growth factors (PDGF, TGF-β) directly to injury site
- Human trials. Mixed results for ACL
- Inconsistent outcomes; some studies show benefit, others show none
- Theoretically sound but highly variable in practice due to preparation inconsistencies